Journals / Pamukkale Tıp Dergisi / 2019 / Cilt: 12 - Sayı: 2

Oral treatment experience in multiple sclerosis at Antalya Training and Research Hospital

Antalya Eğitim ve Araştırma Hastanesi multipl skleroz polikliniğinin oral tedavi deneyimi

Pages
281–288
Publication Date
2022-10-19
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Although the ratio (19.6%) seemed to be lower than the ratio from whole Turkey (41%), the timing of the treatment change have been shown to be in therapeutic window.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: Our aim was to share our oral treatment experience in multiple sclerosis and how we decided to choose the right treatment for our patients.Materials and methods: We analyzed multiple sclerosis patients who were admitted to neurology clinic between 2012-2018.
📊
Key Findings & Data:Demographic features, treatments that were used before initiating oral therapies, in which conditions the treatments were changed to oral therapies (increased relaps rate, progression, activation on magnetic resonance imaging, patient’s choice, adverse events with the previous treatment), the duration of the disease and the oral treatment, Expanded Disability Status Scale (EDSS) scores were all recorded.Results: 550 patients with a definite clinical diagnosis of MS according to the 2010 McDonald criteria were enrolled. 108 (19.6%) patients were receiving oral treatment for multiple sclerosis. 53 patients (49.1%) were receiving fingolimod, 34 patients (31.5%) were receiving dimethylfumarate, 21 patients (19.4%), were receiving teriflunomide.
💡
Conclusion & Impact:Conclusion: Although the ratio (19.6%) seemed to be lower than the ratio from whole Turkey (41%), the timing of the treatment change have been shown to be in therapeutic window.
🔬Design:Research Article
📍Scope:2012-2018 Verileri
⚙️Variables:multipl skleroz · fingolimod · dimetilfumarat

Abstract

Purpose: Our aim was to share our oral treatment experience in multiple sclerosis and how we decided to choose the right treatment for our patients.Materials and methods: We analyzed multiple sclerosis patients who were admitted to neurology clinic between 2012-2018. Demographic features, treatments that were used before initiating oral therapies, in which conditions the treatments were changed to oral therapies (increased relaps rate, progression, activation on magnetic resonance imaging, patient’s choice, adverse events with the previous treatment), the duration of the disease and the oral treatment, Expanded Disability Status Scale (EDSS) scores were all recorded.Results: 550 patients with a definite clinical diagnosis of MS according to the 2010 McDonald criteria were enrolled. 108 (19.6%) patients were receiving oral treatment for multiple sclerosis. 53 patients (49.1%) were receiving fingolimod, 34 patients (31.5%) were receiving dimethylfumarate, 21 patients (19.4%), were receiving teriflunomide. The most evident cause for changing the treatment was the increased relaps rate. Conclusion: Although the ratio (19.6%) seemed to be lower than the ratio from whole Turkey (41%), the timing of the treatment change have been shown to be in therapeutic window.

Özet

Amaç: Bu çalışmanın amacı Sağlık Bilimleri Üniversitesi Antalya Eğitim ve Araştırma Hastanesi multipl skleroz (MS) polikliniğinin oral tedavi deneyimini paylaşmak, hastalar için uygun tedaviyi seçmenin önemini vurgulamaktır. Gereç ve yöntem: 2012-2018 yılları arasında MS polikliniğinde en az 6 aydır düzenli takip edilen 550 hastanın dosyası retrospektif olarak incelendi. Demografik veriler, daha öncesinde kullanmakta olduğu tedaviler ve hangi sebeple (relaps sıklığında artış, progresyon, MR aktivasyonu, hasta isteği, önceki ilaca bağlı yan etki) oral tedavi tercih edildiği, hastalık süreleri ve ne kadar süredir oral tedavi kullanmakta oldukları, hastalık dizabilitesini ölçen Expanded Disability Status Scale (EDSS) skorları kaydedildi. Bulgular: 2010 McDonald kriterlerine göre kesin MS tanısı alan 550 hasta çalışmaya dahil edildi. 108 (%19,6) hasta oral tedavilerden (fingolimod, dimetilfumarat ya da teriflunomid) birini kullanmaktaydı. 53 hasta (%49,1) fingolimod, 34 hasta (%31,5) dimetilfumarat, 21 hasta (%19,4) teriflunomid kullanmaktaydı. En fazla atak sıklığında artış nedeniyle oral tedavi tercih edildiği saptandı. Sonuç: Oral tedavi kulanım oranımız Türkiye ortalamasının altında olsa da bulgularımız, tedavi değişimi yaptığımızda tedavi penceresi içinde kaldığımızı göstermektedir.

🔖

Cite This Article

Yüksel, B., Kurtuluş, F., Erdal, A. (2022). Oral treatment experience in multiple sclerosis at Antalya Training and Research Hospital. Pamukkale Tıp Dergisi, Cilt: 12 - Sayı: 2, 281–288. https://ajindex.com/articles/587174

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Pantazou V, Schluep M, Du Pasquier R. Environmental factors in multiple sclerosis. Presse Med. 2015; http://dx.doi.org/10.1016/ j.lpm.2015.01.001. 2-Wingerchuk DM, Weinshenker BG. Disease modifying therapies for relapsing multiple sclerosis. BMJ 2016;354:i3518 doi: 10.1136/bmj.i3518. 3-Mulero P, Midaglia L, Montalban X. Ocrelizumab:a new milestone in multiple sclerosis therapy. Ther Adv Neurol Disord 2018;Vol.11: 1-6. 4-Multiple Sclerosis Coalition. The use of disease-modifying therapies in multiple sclerosis: principles and current evidence. 2015. http:// ms-coalition.org/cms/images/stories/DMTfullpaper_2015update_final. pdf. 5-Berger JR, Fox RJ. Reassessing the risk of natalizumab-associated PML. J Neurovirol 2016;22:533-5. doi:10.1007/s13365-016-0427- 6 pmid:26843383. 6-Arvin AM, Wolinsky JS, Kappos L et al. Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management. JAMA Neurol. 2015;Jan, 72 (1):31-39. 7-Gold R, Arnold DR, Bar-Or A et al. Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: interim analysis of ENDORSE, a randomized extension study. Mult Scler Houndmills Basingstoke Engl. 2017;Feb;23(2):253-265. 8- Bashir K, Buchwald L, Coyle P. Optimizing immunomodulatory therapy for MS patients. Int J MS Care 2002;3-7. 9-Freedman M, Selchen D, Arnold D et al. Treatment optimization in MS: Canadian MS Working Group updated recommendations. Can J Neurol Sci 2013;40(3):307-23. 10- Smith AL, Cohen JA, Hua LH. Therapeutic targets for multiple sclerosis: current treatment goals and future directions. Neurotherapeutics doi: 10.1007/s13311-017-0548-5. 11- Bates D. Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials. Neurology. 2011;76:S14 –S25. 12-Lublin FD, Baier M, Cutter G. Effect of relapses on development of residual deficit in multiple sclerosis. Neurology. 2003;61:1528 –1532. 13- Comi G, Radaelli M, Soelberg Sorensen P. Evolving concepts in the treatment of relapsing multiple sclerosis. Lancet 2017: 389 (10076), 1347–1356. 14-Bruck W, Stadelmann C. Inflammation and degeneration in multiple sclerosis. J Neurol Sci 2003;24 (Suppl. 5):S265-S26. 15-Leray E, Yaouanq J, Le Page E et al. Evidence for a two-stage disability progression in multiple sclerosis. Brain 2010;133(Pt 7): 1900-1913. 16-Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and progression of irreversible disability in mu